NextCure, Inc. (NXTC): Price and Financial Metrics
NXTC Price/Volume Stats
| Current price | $1.74 | 52-week high | $5.27 |
| Prev. close | $1.68 | 52-week low | $1.16 |
| Day low | $1.67 | Volume | 34,100 |
| Day high | $1.80 | Avg. volume | 83,591 |
| 50-day MA | $1.61 | Dividend yield | N/A |
| 200-day MA | $2.07 | Market Cap | 48.43M |
NXTC Stock Price Chart Interactive Chart >
NextCure, Inc. (NXTC) Company Bio
NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
Latest NXTC News From Around the Web
Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
NextCure to Present at the JMP Securities Life Sciences ConferenceBELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcur |
NextCure Provides Business Update and Reports First Quarter 2023 Financial ResultsClinical data readouts expected in 2023 for NC410, NC762 and NC525 programs First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) Cash of approximately $145 million expected to fund operations into mid-2025 BELTSVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases |
NextCure to Present at 22nd Annual Needham Virtual Healthcare ConferenceBELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure |
NextCure Provides Business Update and Reports Full Year 2022 Financial ResultsClinical data updates expected in 2023 for all three programsNC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML)Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025 BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related dise |
NXTC Price Returns
| 1-mo | 9.43% |
| 3-mo | 16.00% |
| 6-mo | 24.29% |
| 1-year | -58.27% |
| 3-year | -93.53% |
| 5-year | N/A |
| YTD | 23.40% |
| 2022 | -76.50% |
| 2021 | -44.95% |
| 2020 | -80.65% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...